(3R,5S)-7-chloro-5-(2-chlorophenyl)-2,3,4,5-tetrahydro-1-isobutyl-2-oxo-1H-1,4-benzodiazepine-3-acetic acid | 165952-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (3R,5S)-7-chloro-5-(2-chlorophenyl)-2,3,4,5-tetrahydro-1-isobutyl-2-oxo-1H-1,4-benzodiazepine-3-acetic acid
• 英文别名: (3R,5S)-1-Isobutyl-7-chloro-5-(2-chlorophenyl)-2,3,4,5-tetrahydro-2-oxo-1H-1,4-benzodiazepine-3-acetic acid；2-[(3R,5S)-7-chloro-5-(2-chlorophenyl)-1-(2-methylpropyl)-2-oxo-4,5-dihydro-3H-1,4-benzodiazepin-3-yl]acetic acid
• CAS: 165952-81-8
• 化学式: C₂₁H₂₂Cl₂N₂O₃
• 分子量: 421.323
• InChiKey: YHZMPPUZUHYKSR-YLJYHZDGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-2',5-二氯二苯酮 在 N-甲基吗啉 、 sodium tetrahydroborate 、 sodium hydride 、 potassium carbonate 、 溶剂黄146 、 氯甲酸异丁酯 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.25h， 生成 (3R,5S)-7-chloro-5-(2-chlorophenyl)-2,3,4,5-tetrahydro-1-isobutyl-2-oxo-1H-1,4-benzodiazepine-3-acetic acid
  参考文献：
  名称：

  稠合杂环化合物的合成及其对角鲨烯合酶的抑制活性。

  摘要：

  合成了多种稠合的杂环化合物（2-11），作为先导化合物1a的修饰，并评估了它们对角鲨烯合酶的抑制作用。4,1-苯并噻氮平衍生物2、1,4-苯并二氮杂卓衍生物6、1,3-苯并二氮杂卓衍生物7、1-苯并ze庚因衍生物9和4,1-苯并恶唑啉衍生物10有效抑制角鲨烯合酶活性，而4,1-苯并a氮平衍生物1是最有效的抑制剂。发现4，1-苯并噻氮平S-氧化物衍生物4，1,4-苯并二氮杂卓衍生物5，1,3,4-苯并三氮杂卓衍生物8和1,2,3,4-四氢喹啉衍生物11具有弱活性。这些化合物（1a，2、4、5、7和10）的X射线结构比较表明，5-（或6）-苯基的取向对活性很重要。

  DOI：

  10.1016/s0968-0896(01)00289-9

文献信息

• Benzoxazepine and benzothiazepine derivatives useful as antihypertriglyceridemic agents
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0705607A2

  公开（公告）日：1996-04-10

  An antihypertriglyceridemic composition comprising a compound of formula (I) wherein R1 represents a hydrogen atom or a hydrocarbon group that may be substituted; R2 and R3 may be the same or different and each represents a hydrogen atom, a hydrocarbon group that may be substituted, or a heterocyclic group that may be substituted; X' represents a substituent comprising a carboxyl group that may be esterified, a carbamoyl group that may be substituted, a hydroxyl group that may be substituted, an amino group that may be substituted, or an optionally substituted heterocyclic group having a hydrogen atom that may be deprotonated; ring A represents a benzene ring that may be substituted or a heterocyclic ring that may be substituted; ring J' represents a 7- or 8-membered heterocyclic ring having at most 3 hetero-atoms as ring constituent members; and ring J' may have a further substituent in addition to R1, R2, R3 and X', or a pharmacologically acceptable salt thereof. The composition has a plasma triglyceride concentration-lowering activity, and therefore is useful for the prophylaxis or treatment of hyperlipemia, such as hypertriglyceridemia.

  一种抗高三酸甘油酯组合物，包括化合物(I)的结构式，其中R1代表氢原子或可被取代的碳氢基团；R2和R3可以相同或不同，每个代表氢原子，可被取代的碳氢基团，或可被取代的杂环基团；X'代表取代基，包括可酯化的羧基，可被取代的氨基甲酰基，可被取代的羟基，可被取代的氨基，或者是具有可去质子的氢原子的可选取代杂环基团；环A代表可以被取代的苯环或者可以被取代的杂环；环J'代表最多有3个杂原子作为环成员的7-或8-成员杂环，除了R1、R2、R3和X'之外，环J'还可以具有进一步的取代基，或其药学上可接受的盐。该组合物具有降低血浆三酸甘油酯浓度的活性，因此对于预防或治疗高脂血症，如高三酸甘油酯血症，有用。
• Preventives/remedies for organ functional disorders and organ dysfunction
  申请人：——

  公开号：US20040204500A1

  公开（公告）日：2004-10-14

  The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.

  本发明提供了一种用于预防或治疗器官功能障碍的药剂、用于预防或治疗器官功能障碍的药剂以及用于预防或治疗肥胖和其中的脱水症的药剂，每种药剂均包含具有增加泛醌或其盐或其前药的效果的化合物；以及一种增加泛醌的剂量，包括具有角鲨烷合成酶抑制作用或其盐或前药的化合物。
• Condensed cyclic compounds and their use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05698691A1

  公开（公告）日：1997-12-16

  Disclosed is a squalene synthetase inhibitor which comprises the compound represented by the formula ##STR1## wherein R.sub.1 is hydrogen or an optionally substituted hydrocarbon group; R.sub.2 is hydrogen, an optionally substituted alkyl group, an optionally substituted phenyl group or an optionally substituted aromatic heterocyclic ring group; X' is a substituent comprising an optionally esterified carboxyl group, an optionally substituted carbamoyl group, an optionally substituted hydroxyl group, an optionally substituted amino group or an optionally substituted heterocyclic radical having a protonizable hydrogen; Ring A is an optionally substituted benzene ring or an optionally substituted aromatic heterocyclic ring; Ring J' is a 7- to 8-membered heterocyclic ring containing at most three ring constituting hetero atoms; D is C or N; the Ring J' optionally having, besides R.sub.1, R.sub.2 and X', a further substituent; provided that the condensed ring composed of Ring A and ring J' is not a 2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine ring, or a pharmaceutically acceptable salt thereof, and which is useful for the prophylaxis or therapy of hypercholesteremia or coronary sclerosis of mammals.

  本发明涉及一种角鲨烷合成酶抑制剂，其包括如下式所示的化合物：##STR1##其中，R.sub.1是氢或可选取代的碳氢基团；R.sub.2是氢、可选取代的烷基团、可选取代的苯基团或可选取代的芳香族杂环环基团；X'是取代基，包括可选酯化的羧基团、可选取代的氨基甲酰基团、可选取代的羟基团、可选取代的氨基团或可质子化氢的可选取代杂环基团；环A是可选取代的苯环或可选取代的芳香族杂环环；环J'是含有最多三个环构成杂原子的7-至8-成员杂环环；D是C或N；环J'除了R.sub.1、R.sub.2和X'外，还可具有进一步的取代基；但是，由环A和环J'组成的缩合环不是2-氧代-1,2,3,5-四氢-4,1-苯并噁唑环，或其药学上可接受的盐，该化合物对于哺乳动物的高胆固醇血症或冠状动脉硬化的预防或治疗具有用途。
• Agent for preventing or treating organ functional disorders and organ dysfunction
  申请人：Sugiyama Yasuo

  公开号：US20060241096A1

  公开（公告）日：2006-10-26

  The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.

  本发明提供了一种预防或治疗器官功能障碍的药剂、一种预防或治疗器官功能失调的药剂，以及一种预防或治疗肥胖和其代谢障碍的药剂，每种药剂均包含具有增加泛醌或其盐或其前药的效果的化合物；以及一种增加泛醌的药剂，包括具有角鲨烷合酶抑制作用或其盐或其前药的化合物。
• HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL ELEVATING AGENT
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1332763A1

  公开（公告）日：2003-08-06

  A novel high-density lipoprotein(HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.

  一种新型高密度脂蛋白胆固醇升高剂，含有一种具有角鲨烯合成酶抑制活性的化合物。